[Drug therapy for benign prostatic syndrome (BPS)].

Area of Science:

• Urology
• Pharmacology

Background:

• Benign prostatic syndrome (BPS) is commonly treated with alpha1-receptor blockers and 5alpha-reductase inhibitors.
• The placebo effect is significant in BPS drug treatment.

Purpose of the Study:

• To compare the efficacy and side effect profiles of different drug classes used for BPS.
• To evaluate the benefits of combination therapy versus monotherapy for high-risk BPS patients.

Main Methods:

• Review of existing drug treatments for BPS, including alpha1-receptor blockers, 5alpha-reductase inhibitors, and combination therapies.
• Analysis of symptom relief, onset of action, and side effect profiles.

Main Results:

• Alpha1-receptor blockers provide rapid symptom relief and are slightly more effective than 5alpha-reductase inhibitors.
• 5alpha-reductase inhibitors offer volume-dependent symptom relief and reduce BPS complications.
• Combination therapies are superior for high-risk patients but have increased side effects and costs.

Conclusions:

• Drug selection for BPS should consider symptom relief, complication reduction, and patient-specific risk factors.
• Early decision-making between drug treatment and surgery is crucial for managing BPS.